4. Rx or non-Rx drugs or other products known to be sensitive CYP3A4 substrates or CYP3A4 substrates with a narrow therapeutic index, or to be potent inhibitors/inducers of CYP3A4, sensitive substrates of CYP2C9, CYP 2C19, BCRP, and OAT1, which cannot be discontinued 2 weeks prior to Day 1 of dosing and withheld throughout the study until 2 weeks after the last dose of AZD4635.